- Home
- / Editas Medicine
Editas Medicine
Stock Price
$10.6
2023-11-29
Market Capitalization
$866.6 M
2023-11-29
Revenue
$19.7 M
FY, 2022
Editas Medicine Summary
Company Summary
- Overview
- Editas Medicine is a transformative genome editing company that is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. The Company operates through developing and commercializing genome editing technology segment. Editas Medicine is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats technology.
- Type
- Public
- Status
- Active
- Founded
- 2013
- HQ
- Cambridge, MA, US | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Harry Gill, Senior Vice President, Operations
Bruce E. Eaton, Executive Vice President, Chief Technology Officer and Chief Business Officer
Baisong Mei, Senior Vice President and Chief Medical Officer
Operating MetricsView all
Patents Pending
500
FY, 2016
Patents Issued
41
FY, 2016
LocationsView all
3 locations detected
Cambridge, MA HQ
United States
11 Hurley St
Boulder, CO
United States
Westview building, 4909 Nautilus Ct N 208 211boulder
Cambridge, MA
United States
300 Third St
Editas Medicine Financials
Summary Financials
- Revenue (Q3, 2023)
- $5.3M
- Net income (Q3, 2023)
- ($45.0M)
- Cash (Q3, 2023)
- $82.5M
- EBIT (Q3, 2023)
- ($50.2M)
- Enterprise value
- $818.6M